EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease

Aleksandra Gostyńska, Kamila Buzun, Izabela Żółnowska, Violetta Krajka-Kuźniak, Dorota Mańkowska-Wierzbicka, Anna Jelińska, Maciej Stawny

Clinical Nutrition · 2024-09 · 43 (9) · 1952-1971

DOI: 10.1016/j.clnu.2024.07.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Nutrition, 2024-09. Verfasst von Aleksandra Gostyńska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland. Hauptthemen laut MEDLINE: Parenteral Nutrition, Liver Diseases, Intestinal Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parenteral nutrition (PN) is a life-saving procedure conducted to maintain a proper nutritional state in patients with severe intestinal failure who cannot be fed orally. A serious complication of PN therapy is liver failure, known as intestinal failure-associated liver disease (IFALD). The pathogenesis of IFALD is multifactorial and includes inhibition of the farnesoid X receptor (FXR) by PN components, bacteria translocation from impaired intestines, and intravenous line-associated bloodstream infection. Currently, the most frequently researched therapeutic option for IFALD is using lipid emulsions based on soy or fish oil and, therefore, free from phytosterols known as FXR antagonists. Nevertheless, the potential side effects of the lack of soybean oil delivery seem to outweigh the benefits, especially in the pediatric population. PN admixture provides all the necessary nutrients; however, it is deprived of exogenous natural bioactive compounds (NBCs) of plant origin, such as polyphenols, characterized by health-promoting properties. Among them, many substances have already been known to demonstrate the hepatoprotective effect in various liver diseases. Therefore, searching for new therapeutic options for IFALD among NBCs seems reasonable and potentially successful. This review summarizes the recent research on polyphenols and their use in treating various liver diseases, especially metabolic dysfunction-associated steatotic liver diseases (MASLD). Furthermore, based on scientific reports, we have described the molecular mechanism of action of selected NBCs that exert hepatoprotective properties. We also summarized the current knowledge on IFALD pathogenesis, described therapeutic options undergoing clinical trials, and presented the future perspective of the potential use of NBCs in PN therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parenteral NutritionLiver DiseasesIntestinal FailureHumansPolyphenolsReceptors, Cytoplasmic and NuclearAnimalsReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

FXRFarnesoid X receptorIFALDIntestinal failure-associated liver diseaseLiver diseasesParenteral nutrition

Substanzen

PolyphenolsReceptors, Cytoplasmic and NuclearReceptor, Farnesoid X-Activated

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
  • Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland. Electronic address: kbuzun@ump.edu.pl.
  • Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland; Doctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznan, Poland.
  • Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
  • Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland.

Förderung

  • National Science Centre Poland

Zitieren

APA

Gostyńska, A., Buzun, K., Żółnowska, I., Krajka-Kuźniak, V., Mańkowska-Wierzbicka, D., Jelińska, A., & Stawny, M. (2024). Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease. Clinical Nutrition, 43(9), 1952-1971. https://doi.org/10.1016/j.clnu.2024.07.004

Vancouver

Gostyńska A, Buzun K, Żółnowska I, Krajka-Kuźniak V, Mańkowska-Wierzbicka D, Jelińska A, et al. Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease. Clinical Nutrition. 2024;43(9):1952-1971. doi:10.1016/j.clnu.2024.07.004

BibTeX
@article{Gostyska2024,
  author = {Gostyńska, Aleksandra and Buzun, Kamila and Żółnowska, Izabela and Krajka-Kuźniak, Violetta and Mańkowska-Wierzbicka, Dorota and Jelińska, Anna and Stawny, Maciej},
  title = {Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease},
  journal = {Clinical Nutrition},
  year = {2024},
  volume = {43},
  number = {9},
  pages = {1952--1971},
  doi = {10.1016/j.clnu.2024.07.004}
}
Kostenlos starten →